Date: 2018-05-23
Type of information: Nomination
Compound: chief scientific officer
Company: LogicBio Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 23, 2018, LogicBio Therapeutics announced the appointment of Dean Falb as chief scientific officer. Dr. Falb, who most recently served as chief technology officer at Synlogic Therapeutics, brings more than 20 years of drug discovery and development experience to the LogicBio leadership team. As chief technology officer and co-founder of Synlogic, Falb led the company’s effort to develop engineered synthetic microbes for rare disease and oncology applications. Prior to Synlogic, he was an entrepreneur in residence at Atlas Ventures, where he helped guide the launch of several early stage life sciences companies. From 2005 to 2012, he served as vice president of research at Stryker Regenerative Medicine. In this role, Dr. Falb led the discovery and development of a portfolio of bone morphogenic protein drugs in osteoarthritis. He has also held leadership positions at Praecis Pharmaceuticals, NeoGenesis Pharmaceuticals, and Millennium Pharmaceuticals. He received his doctoral degree in biochemistry and molecular biology from Harvard University.
- As chief scientific officer, Dr. Falb will guide research strategy and drive innovation as LogicBio advances multiple product development programs into the clinic.
Financial terms:
Latest news:
Is general: Yes
